Our results add to the existing literature and show that HER2-low tumors are entities that differ little from HER2-zero tumors when the existing dichotomy between HR+ and HR– tumors is taken into account, as well as other classical clinicopathological prognostic or predictive factors of breast cancers. Here, ERBB2 is linked to breast carcinoma.